what is glp 1 retatrutide Triple Agonist Peptide | cGMP retatrutide triple agonist gip glp-1

In a Phase 2 clinical trial published in the New England Journal of Medicine (2023), the compound demonstrated unprecedented metabolic effects: Average weight reduction: 24.2% of total body weight at 48 weeks (24mg dose)

This is typically the fastest weight loss phase, with weekly losses of 1.2 to 1.8 pounds common at full doses

Currently available incretin (metabolic hormones) therapies activate either the GLP-1 receptor or both GIP and GLP-1 receptors, but glucagon is the additional edge in retatrutide

To better understand how these treatments work in detail, you can also explore the full guides on semaglutide guide and liraglutide guide, which explain effectiveness, usage, and differences in a simple way